Plain-English translation of NCT04545762 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing anti-CD19 chimeric antigen receptor T cells (CAR-T cells), a new type of treatment for certain lymphomas that have stopped responding to other therapies. Doctors collect your own immune cells, modify them in a laboratory to help them recognize and attack cancer cells, and then infuse them back into your body. This study is checking whether this treatment is safe and at what dose it works best.
Many patients with certain types of lymphoma run out of treatment options when their cancer comes back or doesn't respond to standard chemotherapy. This medication offers a new approach by using your own immune system to fight the cancer, potentially offering hope to those with limited choices.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will first have an apheresis procedure (similar to a blood donation) where doctors collect your immune cells over one day. The cells are then sent to a laboratory where they are modified for about 2 weeks while you receive two chemotherapy drugs to prepare your body. Once ready, you receive an infusion of the modified cells, which typically takes 5–30 minutes. After that, you'll have follow-up visits for safety checks at 30 days and then up to 12 months, with long-term follow-up for up to 15 years to monitor how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States